Institution

Charité – Universitätsmedizin Berlin

Berlin, GermanyWebsite

Also known as: Charité · Charité - Universitätsmedizin Berlin · Charité Universitätsmedizin Berlin

745running trials
334closed trials
1researcher
162,205publications (OpenAlex)

Researchers

Felix Ehret

Running trials

Not yet recruiting
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source
Not yet recruiting
IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
NCT07888647· Phase 2· German Cancer Research Center· Source
Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
Stratification and Treatment in Early Psychosis Study -ASSIST
NCT07326124· Phase 3· University of Oxford· Source
Not yet recruiting
A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease
NCT07431294· Phase 1· Bayer· Source
Not yet recruiting
Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis
2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source
Not yet recruiting
Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR
2024-517295-37-00· Phase 3· University Of Cologne· Source
Not yet recruiting
CD19-B Cell Depletion in PAIS-ME/CFS Patients
NCT07724834· Phase 2· Charite University, Berlin, Germany· Source
Not yet recruiting
Post-intervention dual antiplatelet therapy for mild stroke
2026-525681-22-00· Phase 3· Technische Universitaet Dresden· Source
Recruiting
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
NCT07778667· Phase 3· Idorsia Pharmaceuticals Ltd.· Source
Not yet recruiting
PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%
NCT07877584· Phase 3· German Cancer Research Center· Source
Not yet recruiting
DETECTRA: Remote Monitoring to Detect Rheumatoid Arthritis Flares and Treatment Response
NCT07857993· Centre Hospitalier Universitaire Vaudois· Source
Recruiting
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
NCT07781657· Phase 2· Hoffmann-La Roche· Source
Recruiting
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
NCT07781644· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
NCT07825064· Phase 2· Hoffmann-La Roche· Source
Recruiting
Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations
NCT07789574· Phase 2· Thomas Ernst, Prof. Dr. med.· Source
Not yet recruiting
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· Phase 3· Almirall, S.A.· Source
Not yet recruiting
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT07116473· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Not yet recruiting
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
2026-525367-40-00· Phase 3· AstraZeneca AB· Source
Not yet recruiting
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)
2025-522648-42-01· Phase 2/3· Crinetics Pharmaceuticals Inc.· Source
Not yet recruiting
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden
NCT07715396· Phase 3· AIO-Studien-gGmbH· Source
Not yet recruiting
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
2025-522019-40-00· Phase 1/2· Novartis Pharma AG· Source
Recruiting
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Recruiting
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
2025-524641-27-00· Phase 3· K-Group Beta Inc.· Source
Not yet recruiting
Assessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate
NCT07888322· Aristotle University Of Thessaloniki· Source
Recruiting
Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source
Recruiting
Stratification and Treatment in Early Psychosis Study - ENHANCE
NCT06778564· Phase 3· University of Oxford· Source
Not yet recruiting
Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source
Not yet recruiting
Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)
NCT07714213· Phase 2· Christiana Franke· Source
Not yet recruiting
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
NCT07004413· Phase 3· Charite University, Berlin, Germany· Source
Not yet recruiting
A Study to Investigate the Effects of Cleminorexton Compared with Placebo in the Treatment of Participants with Central Disorders of Hypersomnolence
2026-525961-37-00· Phase 2/3· Centessa Pharmaceuticals UK Limited· Source
Recruiting
Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)
NCT05880524· Phase 2· Ludwig-Maximilians - University of Munich· Source
Recruiting
A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
2026-525328-10-00· Phase 2· Medica Scientia Innovation Research S.L.· Source
Not yet recruiting
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
NCT07474649· Phase 3· Daiichi Sankyo· Source
Not yet recruiting
Pix-Risk: Early Detection of Rheumatoid Arthritis Via the DETECTRA Platform
NCT07825233· Centre Hospitalier Universitaire Vaudois· Source
Not yet recruiting
A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
2026-526184-38-00· Phase 2· Enveda Therapeutics Inc.· Source
Recruiting
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
NCT07751991· Phase 1· Charm Therapeutics· Source
Recruiting
Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer
NCT07860047· Phase 2· University Hospital Tuebingen· Source
Recruiting
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· Phase 3· Janssen Cilag International· Source
Recruiting
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial
2025-521209-42-00· Phase 4· Fondazione GONO G.I.· Source
Recruiting
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
NCT07830719· Phase 2· Novartis Pharmaceuticals· Source
Not yet recruiting
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
NCT07719348· Phase 1/2· Servier· Source
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· Phase 3· Incyte Corp.· Source
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Incyte Corporation· Source
Not yet recruiting
A Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney Function
NCT07808788· Phase 1· Novo Nordisk A/S· Source
Recruiting
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
2025-523285-25-00· Phase 3· AstraZeneca AB· Source
Not yet recruiting
AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia
2025-522190-11-01· Phase 3· Universitaetsklinikum Schleswig-Holstein AöR· Source
Recruiting
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
NCT07010302· Phase 4· Massachusetts General Hospital· Source

Showing 50 of 745.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Childhood cancers51 recruiting
Lung cancer33 recruiting
Colorectal cancer29 recruiting
Acute lymphoblastic leukaemia19 recruiting
Melanoma18 recruiting
Heart failure15 recruiting
Liver and biliary tract cancer15 recruiting
Ovarian cancer15 recruiting
Pancreatic cancer14 recruiting
Stroke14 recruiting
Crohn's disease13 recruiting
Prostate cancer13 recruiting
Multiple myeloma12 recruiting
Ulcerative colitis11 recruiting
Acute myeloid leukaemia10 recruiting
Gastric and oesophageal cancer10 recruiting
Atopic dermatitis (eczema)9 recruiting
Atrial fibrillation9 recruiting
Chronic myeloid leukaemia9 recruiting
Head and neck cancer9 recruiting
Lupus (SLE)9 recruiting
Chronic lymphocytic leukaemia8 recruiting
Coronary artery disease8 recruiting
Depression8 recruiting
Metastatic breast cancer8 recruiting
Multiple sclerosis8 recruiting
Myasthenia gravis8 recruiting
Bladder cancer7 recruiting
Chronic kidney disease7 recruiting
Cystic fibrosis7 recruiting
Endometrial cancer7 recruiting
Myelodysplastic syndromes7 recruiting
Neuroblastoma7 recruiting
Rheumatoid arthritis7 recruiting
Schizophrenia7 recruiting
Amyloidosis6 recruiting
Bronchiectasis6 recruiting
Kidney cancer6 recruiting
Liver cirrhosis6 recruiting
Obesity6 recruiting
Parkinson disease6 recruiting
Sarcoma6 recruiting
Alzheimer disease5 recruiting
Fatty liver disease (MASLD/MASH)5 recruiting
Mantle cell lymphoma5 recruiting
Systemic sclerosis (scleroderma)5 recruiting
ALS (motor neurone disease)4 recruiting
Cervical cancer4 recruiting
Dermatomyositis and polymyositis (myositis)4 recruiting
Follicular lymphoma4 recruiting
High blood pressure4 recruiting
Long COVID and ME/CFS4 recruiting
Ankylosing spondylitis3 recruiting
CIDP (chronic inflammatory demyelinating polyneuropathy)3 recruiting
Diffuse large B-cell lymphoma3 recruiting
Duchenne muscular dystrophy3 recruiting
Glioblastoma3 recruiting
Hepatitis B3 recruiting
Hidradenitis suppurativa3 recruiting
HIV3 recruiting
Hodgkin lymphoma3 recruiting
Huntington's disease3 recruiting
Immune thrombocytopenia (ITP)3 recruiting
Macular degeneration3 recruiting
Myeloproliferative neoplasms3 recruiting
Osteoarthritis3 recruiting
Psoriasis3 recruiting
Psoriatic arthritis3 recruiting
ANCA-associated vasculitis2 recruiting
Dystonia2 recruiting
Narcolepsy2 recruiting
Neuroendocrine tumours2 recruiting
Polycystic kidney disease2 recruiting
Primary biliary cholangitis2 recruiting
Sjögren's disease2 recruiting
Triple-negative breast cancer2 recruiting
Alopecia areata1 recruiting
Aortic stenosis1 recruiting
Bipolar disorder1 recruiting
Brain aneurysm1 recruiting
Coeliac disease1 recruiting
Congenital heart disease1 recruiting
COPD1 recruiting
Cushing's syndrome1 recruiting
Cytomegalovirus infection1 recruiting
Epilepsy1 recruiting
Fabry disease1 recruiting
Familial hypercholesterolaemia1 recruiting
Hypertrophic cardiomyopathy1 recruiting
Hypothyroidism1 recruiting
IgA nephropathy1 recruiting
Mesothelioma1 recruiting
Migraine1 recruiting
Multiple system atrophy1 recruiting
Myocarditis1 recruiting
Neuromyelitis optica (NMOSD)1 recruiting
Peripheral artery disease1 recruiting
Sickle cell disease1 recruiting
Spinal muscular atrophy1 recruiting
Thalassaemia1 recruiting
Thyroid cancer1 recruiting
Type 2 diabetes1 recruiting
Vascular dementia1 recruiting
Vitiligo1 recruiting

Closed trials

Recruiting
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
NCT07630974· Phase 1/2· Merck Sharp & Dohme LLC· Source
Withdrawn
Confirmatory Study of Govorestat in CMT-SORD
NCT07191912· Phase 3· Applied Therapeutics, Inc.· Source
Completed
Ovarian Cancer Screening and AI
NCT07503054· Charite University, Berlin, Germany· Source
Completed
Essentiale® liquid once-daily Phase III study
2025-521678-32-00· Phase 3· Opella Healthcare Group S.A.S.· Source
Completed
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease
2024-516966-12-00· Phase 2· Novartis Pharma AG· Source
Completed
A multi-part, adaptive, Phase 1, first time in human study in healthy participants and participants with atopic dermatitis (AD) to assess the safety, tolerability, pharmacokinetics (PK) of single ascending (SAD), multiple ascending doses (MAD) and selected dose of SYX-5219 (AD Participants)
2025-522216-17-00· Phase 1· Sitryx Therapeutics Limited· Source
Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT07227012· Phase 1/2· Pfizer· Source
Completed
Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)
NCT06984328· Phase 2· Genmab A/S· Source
Active, not recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203· Phase 2· Iovance Biotherapeutics, Inc.· Source
Active, not recruiting
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037· Phase 2· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
NCT07246941· Phase 1· Hoffmann-La Roche· Source
Completed
Clinical Study to Estimate Bone Mineral Density With the POROUS Ultrasound Device
NCT07187518· POROUS GmbH· Source
Completed
A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)
NCT06453668· Phase 1· Itb-Med AB· Source
Active, not recruiting
Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)
2025-521681-10-00· Phase 2· Revolution Medicines Inc.· Source
Completed
Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection
2024-519856-94-00· Phase 2· Biomx Ltd.· Source
Completed
A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer (NeoTRACE)
2024-517561-16-00· Phase 2· AIO-Studien gGmbH· Source
Completed
A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors
2024-514745-10-00· Phase 1· Pfizer Inc.· Source
Active, not recruiting
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC)
2024-517818-15-00· Phase 1/2· Merck Healthcare KGaA· Source
Completed
Molecular effects of deucravacitinib on plaque psoriasis and hard-to-treat psoriasis sites.
2023-508948-22-00· Phase 4· Charite Universitaetsmedizin Berlin KöR· Source
Completed
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis
2024-517814-13-00· Phase 2· Janssen Cilag International· Source
Completed
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.
NCT06637631· Phase 2· Sanofi-Aventis Recherche & Developpement· Source
Active, not recruiting
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567· Phase 1/2· GlaxoSmithKline· Source
Active, not recruiting
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293· Phase 3· AbbVie· Source
Active, not recruiting
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06291220· Phase 1· AbbVie· Source
Terminated
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
NCT06555328· Phase 2· InflaRx GmbH· Source
Completed
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
NCT06664801· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source
Completed
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT06624228· Phase 3· UCB Biopharma SRL· Source
Active, not recruiting
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185· Phase 1· Eli Lilly and Company· Source
Completed
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection
NCT06615921· Takeda· Source
Completed
Prospective Evaluation of Frailty in Patients With Head and Neck Tumors Before Curative Intended Therapy
NCT06638216· Charite University, Berlin, Germany· Source
Completed
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder
NCT06029439· Phase 3· Neumora Therapeutics Inc.· Source
Completed
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa
2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Completed
A safety study of PF-08046044/SGN-35C in adults with advanced cancers
NCT06254495· Phase 1· Seagen Inc.· Source
Completed
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT06335303· Phase 2· Boehringer Ingelheim· Source
Completed
A study to see how safe and effective the drug Luveltamab Tazevibulin (STRO-002) is in treating infants and children under 12 years old with a specific type of acute myeloid leukemia (AML)
2023-506240-16-00· Phase 1/2· Sutro Biopharma Inc.· Source
Completed
A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine
2023-507942-10-00· Phase 2· Boehringer Ingelheim International GmbH· Source
Completed
Immunological and functional characteristics of T memory-like cells in psoriasis under treatment with deucravacitinib.
2024-510759-37-00· Phase 4· Charite Universitaetsmedizin Berlin KöR· Source
Completed
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112· Phase 3· Alumis Inc· Source
Completed
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia
2023-508819-23-00· Phase 1· Hutchmed Ltd.· Source
Completed
Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome (REVIVE)
2024-511628-16-00· Phase 2· Goethe University Frankfurt· Source
Completed
Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
NCT06506773· Vertex Pharmaceuticals Incorporated· Source
Completed
Phase 2a, double-blind, randomized, placebo-controlled trial of methylprednisolone versus placebo in patients with cognitive deficits in post-COVID-19 syndrome (PCS) - PoCoVIT
2023-504826-21-00· Phase 2· Charite Universitaetsmedizin Berlin KöR· Source
Completed
Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction
2023-506210-40-00· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )
NCT06341712· Phase 2· Ipsen Innovation· Source
Completed
A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.
NCT06431763· Phase 4· Novartis Pharmaceuticals· Source
Completed
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
NCT06430671· Phase 1· Cellerys AG· Source
Completed
Efficacy of an Online-Based Self-Help Intervention for Auditory Hallucinations in Persons With Psychotic Disorders
NCT06186570· Charite University, Berlin, Germany· Source
Active, not recruiting
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06082167· Phase 2/3· Exelixis· Source
Terminated
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
NCT06444451· Phase 2· Sanofi· Source

Showing 50 of 334.

Registry name variants (135)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Charite Universitaetsmedizin Berlin KöR
Berlin, 13125
779 trials
Charité Universitätsmedizin Berlin
Berlin, 13353
123 trials
Charite Universitatsmedizin Berlin KöR
Berlin, 12203
37 trials
Charité - Universitaetsmedizin Berlin
Berlin, 10117
25 trials
Charité - Universitätsmedizin
Berlin, 13353
10 trials
Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin
Berlin, 12200
10 trials
Charite
Berlin, 10117
8 trials
Charité Universitaetsmedizin Berlin - Campus Mitte
Berlin, 10117
8 trials
Charité - University Medicine Berlin
Berlin, 13353
8 trials
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin
Berlin, 12203
5 trials
Charité - Universitätsmedizin Berlin Campus Mitte
Berlin, 10115
4 trials
Charité - Universitätsmedizin Berlin (CVK)
Berlin, 13353
4 trials
Charité - Campus Charité Mitte
Berlin, 10117
3 trials
- NCT07070232A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- NCT06644781A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- NCT05531565A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Charité - Paediatric Pulmonology Department
Berlin
3 trials
- NCT06506773Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
- NCT05076149A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
- NCT05033080A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
Charite-Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)
Berlin, 10117
3 trials
- NCT05855109Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
- NCT06055725A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
- NCT06734117A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome
Charite Universitaetsmedizin Berlin, Campus Virchow
Berlin, 13353
3 trials
- NCT07037433Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- NCT07037459Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- NCT06252649Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Charité - Universitätsmedizin Berlin (CBF)
Berlin, 12203
3 trials
- NCT05665608Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation
  Contact: Gerhard Hindricks, Prof
- NCT04592874A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
- NCT04298723Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.
  Contact: Carsten Skurk, Prof. Dr.
Centre of Muscle and Bone Research (ZMK), Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
Berlin, State of Berlin 12207
2 trials
- NCT07187518Clinical Study to Estimate Bone Mineral Density With the POROUS Ultrasound Device
- NCT06567054Clinical Study to Predict the Risk of Bone Fractures With the POROUS Ultrasound Device
Charité - Campus Charité Mitte - Charité Research Organisation GmbH
Berlin, 10117
2 trials
- NCT07808788A Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney Function
  Contact: Novo Nordisk
- NCT06267092A Study of How CagriSema Works on Appetite in People With Excess Body Weight
Charité - Universitaetsmedizin Berlin - Campus Bejnamin Franklin
Berlin, 10117
2 trials
- NCT07106762Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
  Contact: Maria De Santis, Site 0154
- NCT07015983A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF)
Berlin, State of Berlin 12203
2 trials
- NCT07499232A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- NCT06153693Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
Charite Universitaetsmedizin Berlin - Campus Charite Mitte
Berlin, 12203
2 trials
- NCT07441694Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- NCT05233410Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2
Charité - Universitätsmedizin Berlin Campus Virchow
Berlin
2 trials
- NCT04459715A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
- NCT03112980Randomized Trial of TAVI vs. SAVR in Patients With Severe Aortic Valve Stenosis at Low to Intermediate Risk of Mortality
Charité - Universitätsmedizin Berlin CCM
Berlin, 10117
2 trials
- NCT05665608Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation
  Contact: Gerhard Hindricks, Prof
- NCT05007132Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Charité-Universitätsmedizin Berlin, Department of Pediatric Oncology/Hematology
Berlin, 13353
2 trials
- NCT07647471Evaluation of an Exercise Intervention During Intensive Medical Treatment in Pediatric Oncology.
  Contact: Pablo Hernaiz Driever
- NCT03559413Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL
Dpt of Dermatology and Allergology, Charité - Universitätsmedizin Berlin
Berlin, State of Berlin 10117
2 trials
- NCT05098821Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation
- NCT05099315Microbiome in Atopic Dermatitis Under Systemic Therapy
  Contact: Sabine Dölle-Bierke, PhD
Universitätsmedizin Berlin Charité
Berlin, 13353
2 trials
- NCT05174650Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
- NCT02701036Sporadic Degenerative Ataxia With Adult Onset: Natural History Study
  Contact: Sarah Doss, MD
Center for ALS and other motor neuron disorders, Charité - Universitätsmedizin Berlin
Berlin, 13353
1 trial
- NCT05852405Clinical Characteristics, Natural History, Health Care Measures, and Genetic Screening in Patients With ALS
Center for Stroke Research Berlin, Charité Universitätsmedizin Berlin
Berlin, 10117
1 trial
- NCT01364168Prospective Cohort With Incident Stroke
  Contact: Martin Dichgans, Prof.
Charite Berlin Universitatsmedizin
Berlin, 13353
1 trial
- NCT05611931Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Charité - Berlin University of Medicine
Berlin, 10117
1 trial
- NCT05714930LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus
  Contact: Tobias Alexander, MD
Charite, Dept of Nephrology
Berlin, 10117
1 trial
- NCT06615921A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection
Charité, III. Medizinische Abteilung (Hämatologie/Onkologie)
Berlin, 12200
1 trial
- NCT05804032Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin /ID# 259413
Berlin, 12203
1 trial
- NCT05599984Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Charite Universitaetsmedizin Berlin - Campus Berlin Buch
Berlin, 13125
1 trial
- NCT04241068A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Charité Universitaetsmedizin Berlin - Campus Mitte-Department of Endocrinology and Metabolism (Site 0503)
Berlin, 10117
1 trial
- NCT04924075Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
  Contact: Study Coordinator
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 129115
Berlin, 10117
1 trial
- NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 129117
Berlin, 10117
1 trial
- NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 153896
Berlin, 10117
1 trial
- NCT03047395A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 248979
Berlin, 10117
1 trial
- NCT05494606An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 262462
Berlin, 10117
1 trial
- NCT05841537An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 264097
Berlin, 10117
1 trial
- NCT05930275Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 275760
Berlin, 10117
1 trial
- NCT06543914Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 275884
Berlin, 10117
1 trial
- NCT06764706Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 0301)
Berlin, 10117
1 trial
- NCT03834519Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 0401)
Berlin, 10117
1 trial
- NCT06307431A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 0504)
Berlin, 10117
1 trial
- NCT04456699Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 0901)
Berlin, 10117
1 trial
- NCT04776148Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
Charite - Universitaetsmedizin Berlin (CCM)
Berlin, 10117
1 trial
- NCT06319820A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Charite Universitaetsmedizin Berlin (Site 1101)
Berlin, 13353
1 trial
- NCT03675737Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
Charite Universitaetsmedizin Berlin (Site 1321)
Berlin, 10117
1 trial
- NCT04586231A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Charité - Universitätsmedizin Berlin
Mitte, State of Berlin 10117
1 trial
- NCT07503054Ovarian Cancer Screening and AI
Charité - Universitätsmedizin Berlin, BeMoveD - Berlin Movement Diagnostics
Berlin, 10117
1 trial
- NCT06596824Personalized Digital Training Intervention to Reduce Inflammation by Correcting Pathological Movement Patterns in Pre-stage Knee Osteoarthritis After Anterior Cruciate Ligament Reconstruction
  Contact: Winkler, Prof. Dr.med.
Charite Universitatsmedizin Berlin (Benjamin Franklin Campus)
Berlin
1 trial
- NCT02227251Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
Steglitz, State of Berlin 1220
1 trial
- NCT04730518Yoga-based Group Intervention (YoGI) for In-patients With Schizophrenia Spectrum Disorders
  Contact: Kerem Böge, Dr.
Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Campus Charité Mitte
Berlin, State of Berlin 12203
1 trial
- NCT07265180Oxytocin-Augmented Group Psychotherapy for Patients With Schizophrenia - an Oxytocin-dose Comparison
  Contact: Marco Zierhut, MD
Charité - Universitätsmedizin Berlin - Campus Charité Mitte
Berlin, 10117
1 trial
- NCT03106324A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant
Charité-Universitätsmedizin Berlin (CCM), Department of Psychiatry and Psychotherapy, , Charitéplatz 1, D-10117 Berlin, Germany
Berlin, State of Berlin 10117
1 trial
- NCT07645443FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
  Contact: Kerem Böge, Prof. Dr. Dr
Charité Universitätsmedizin Berlin, DHZC - Campus Charité Mitte
Berlin, 10117
1 trial
- NCT06026345Affera Global Registry
Charité - Universitätsmedizin Berlin Funktionsdiagnostik und Stationen, Cardiology
Berlin, 10117
1 trial
- NCT03237494TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects
Charité - Universitätsmedizin Berlin, Psoriasis-Forschungs- und BehandlungsCentrum
Berlin, State of Berlin 10117
1 trial
- NCT06905028Exploratory Clinical Study on Fasting in Psoriasis and Psoriatic Arthritis (RiseFast)
Charite - Universitätsmedizin Berlin - Sozialpädiatrisches Zentrum
Berlin, 13353
1 trial
- NCT03678753Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
Charité - Universitätsmedizin Berlin (Surgical)
Berlin
1 trial
- NCT06285643A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
Charite Universitatsmedizin Berlin (Virchow Campus)
Berlin
1 trial
- NCT02227251Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Charité - University Medicine Berlin - Campus Benjamin Franklin
Berlin, Hindenburgdamm 30 12203 Berlin
1 trial
- NCT04829929Evaluation of Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk
Charité - University Medicine Berlin Department of Neurosurgery
Berlin, 10117
1 trial
- NCT07888647IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
  Contact: Michael Platten, Prof. Dr. med.
Charité - University Medicine Berlin, Dept. of Haematology, Medical Oncology and Tumor Immunology, Campus Benjamin Franklin
Berlin, 12200
1 trial
- NCT02936388Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis
Charité, University of Berlin
Berlin
1 trial
- NCT06295094The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.
  Contact: Beate Rau, PhD
Charite - Universtitatsmedizin Berlin CCM (Site 0269)
Berlin, 10117
1 trial
- NCT04003636Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Clinical Research Center for Hair and Skin Science, Dept of Dermatology, Charité Universitätsmedizin Berlin
Berlin, 10117
1 trial
- NCT05041803European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Department of Endocrinology and Metabolism, Charité Universitätsmedizin Berlin, Campus Mitte
Berlin, 10117
1 trial
- NCT07187518Clinical Study to Estimate Bone Mineral Density With the POROUS Ultrasound Device
Department of General, Visceral and Vascular Surgery, Charité, University Medicine Berlin, Campus Benjamin Franklin Berlin
Berlin
1 trial
- NCT04678583Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer
  Contact: Jürgen Weitz, Prof Dr med
Department of Neurology, Charite, Berlin Germany and Center for Stroke Research (CSB)
Berlin, 10117
1 trial
- NCT06823466Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants
  Contact: Christian Nolte, MD, PhD
Department of Neuroradiology, Charite
Berlin, State of Berlin 13353
1 trial
- NCT07888322Assessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate
  Contact: Jawed Nawabi, MD, MHBA, MSc
Department of Neurosurgery, Charité - Universitätsmedizin Berlin
Berlin, 13353
1 trial
- NCT02258919Decompressive Hemicraniectomy in Intracerebral Hemorrhage
Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin
Berlin, 13353
1 trial
- NCT05858437Impact of Propionic Acid on Regulatory T Cell Function in Children With CKD
  Contact: Johannes Holle, MD
Department of Radiooncology and Radiotherapy, Charité-Universitätsmedizin Berlin
Berlin
1 trial
- NCT05337631Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
  Contact: Alexander Rühle, MD, MHBA
Department of Rheumatology, Charité Universitätsmedizin Berlin, Charite Campus Mitte
Berlin, State of Berlin 10117
1 trial
- NCT06567054Clinical Study to Predict the Risk of Bone Fractures With the POROUS Ultrasound Device
Duplicate_Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 222963
Berlin, 10117
1 trial
- NCT04451772A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
Duplicate_Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 98124
Berlin, 10117
1 trial
- NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Fabry disease center Berlin - Charité - Universitätsmedizin Berlin
Berlin
1 trial
- NCT06095713German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa
Institute for Experimental Pediatric Endocrinology, Charité Universitätsmedizin Berlin
Berlin, 13353
1 trial
- NCT07302802Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
  Contact: Peter Kühnen, Prof. Dr.
2760203 - Charité
Berlin, 10117
2760211 - Charité - Universitätsmedizin Berlin
Berlin, 10117
Charité, Campus Benjamin Franklin , III. Medizinische Abteilung (Hämatologie/Onkologie)
Berlin, 12200
Charite - Campus Benjamin Franklin (Site # 0701)
Berlin, 12200
Charité - Campus Charité Mitte - Charité Comprehensive Cancer Center
Berlin, 10117
Charité, III. Medizinische Abteilung
Berlin, 12200
Charité / Pädiatrie
Berlin, 13353
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin /ID# 263433
Berlin, 12203
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin /ID# 266366
Berlin, 12203
Charité Universitaetsmedizin Berlin - Campus Ch
Berlin, 10117
Charite Universitaetsmedizin Berlin - Campus Charite Mitte (CCM) - Rheumatology
Berlin, 10117
Charité Universitaetsmedizin Berlin - Campus Mitte-Hauttumorcentrum Charité (HTCC) (Site 1302)
Berlin, 10115
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 257310
Berlin, 10117
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 258076
Berlin, 10117
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 260294
Berlin, 10117
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 263076
Berlin, 10117
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 263955
Berlin, 10117
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 265752
Berlin, 10117
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 267310
Berlin, 10117
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 267411
Berlin, 10117
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 274545
Berlin, 10117
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 0304)
Berlin, 10117
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 0352)
Berlin, 10117
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 0369)
Berlin, 13353
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 0400)
Berlin, 10117
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 0604)
Berlin, 10117
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 0609)
Berlin, 10117
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 0679)
Berlin, 10117
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 0800)
Berlin, 10117
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 1022)
Berlin, 10117
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 1101)
Berlin, 10117
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 1203)
Berlin, 10117
Charité Universitaetsmedizin Berlin - Campus Mitte (Site 1312)
Berlin, 10117
Charite Universitaetsmedizin Berlin KöR
Mitte, State of Berlin 10117
Charite - Universitaetsmedizin Berlin - Neurology
Berlin
Charite-Universitaetsmedizin Berlin (Site 0191)
Berlin, 13353
Charite Universitaetsmedizin Berlin (Site 0442)
Berlin, 13353
Charite Universitaetsmedizin Berlin (Site 0515)
Berlin, 10117
Charite Universitaetsmedizin Berlin (Site 0609)
Berlin, 13353
Charite Universitaetsmedizin Berlin (Site 1301)
Berlin, 10117
Charite-Universitätsmedizin Berlin - Berlin
Berlin, 13353
Charité Universitätsmedizin Berlin, Campus Benjamin Franklin (CBF)
Berlin, 12203
Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin - Studienzentrale Onkologie
Berlin, Beriln 12203
Charite Universitatsmedizin Berlin, Campus Mitte (CCM) Allergie Center
Berlin, 10117
Charité - Universitätsmedizin Berlin (CBF) - Hindenburgdamm 30
Berlin, 12203
Charite - Universitatsmedizin Berline
Berlin, 10117
Charité - Universitätsmedizin Berlin, Merz Investigational Site #0490398
Berlin, 10117
Charité Universitätsmedizin Berlin, Neurologische Ambulanz, Kopfschmerzambulanz
Berlin, 10117
Charité - Universitätsmedizin Berlin SPZ Abteilung Neuropaediatrie
Berlin, 13353
Charite - Universtitatsmedizin Berlin CCM (Site 0708)
Berlin, 10117
Department of Cardiology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin
Berlin
Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte
Berlin, B 10117
Duplicate_Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 212220
Berlin, 10117

Conditions

Diseases this institution publishes on or runs trials for.

Stroke299 works · 24 trials
Heart failure298 works · 26 trials
Obesity191 works · 15 trials
Schizophrenia153 works · 10 trials
Chronic kidney disease124 works · 20 trials
Atrial fibrillation121 works · 15 trials
Alzheimer disease113 works · 22 trials
Type 2 diabetes95 works · 5 trials
Asthma88 works · 1 trial
Multiple sclerosis88 works · 15 trials
Liver and biliary tract cancer85 works · 36 trials
Parkinson disease84 works · 10 trials
Ovarian cancer79 works · 36 trials
Colorectal cancer78 works · 52 trials
Depression77 works · 15 trials
Cystic fibrosis73 works · 22 trials
Osteoarthritis71 works · 3 trials
Fatty liver disease (MASLD/MASH)70 works · 11 trials
Melanoma61 works · 45 trials
Myasthenia gravis60 works · 15 trials
Psoriasis59 works · 21 trials
Epilepsy58 works · 5 trials
Migraine58 works · 16 trials
Rheumatoid arthritis57 works · 12 trials
Prostate cancer57 works · 24 trials
Bipolar disorder55 works · 1 trial
Coronary artery disease49 works · 15 trials
Tuberculosis42 works · 0 trials
Atopic dermatitis (eczema)42 works · 28 trials
COPD41 works · 2 trials

Institution data: ROR 001w7jn25 (CC0-1.0)Updated 12 Nov 2026

Report an error